Top

Published in:

01-06-2021 | Glioma | Clinical Study

PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression

Authors: Jonathan Weller, Sophie Katzendobler, Philipp Karschnia, Stefanie Lietke, Rupert Egensperger, Niklas Thon, Michael Weller, Bogdana Suchorska, Joerg-Christian Tonn

Published in: Journal of Neuro-Oncology | Issue 2/2021

Abstract

Introduction

The role of chemotherapy alone in newly diagnosed WHO grade 2 oligodendroglioma after biopsy, incomplete or gross total resection remains controversial. We here analyze the clinical outcome of four patient cohorts being treated with either procarbazine, CCNU and vincristine (PCV) or temozolomide (TMZ) after biopsy, resection only, or wait-and-scan after biopsy.

Methods

Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy (n = 26) or PCV (n = 30) after biopsy. Presurgical MRI T2 tumor volumes were obtained by manual segmentation. Progression-free survival (PFS), post-recurrence PFS (PR-PFS) and rate of histological progression to grade 3 were analyzed.

Results

PFS was longest after PCV (9.1 years), compared to 5.1 years after W&S, 4.4 years after RES and 3.6 years after TMZ. The rate of histological progression from grade 2 to 3 within 10 years was 9% for the PCV, 29% for the W&S, 67% for the RES and 75% for the TMZ group (p = 0.01). In the W&S group, patients treated with PCV at first relapse had a longer PFS from intervention than those treated with TMZ (7.2 vs 4.0 years, p = 0.04). Multivariate analysis identified smaller tumor volume prior to any intervention (p = 0.02) to be prognostic for PFS.

Conclusions

PCV chemotherapy alone is an effective treatment for WHO grade 2 oligodendroglioma, with long PFS and low rate of histological progression.

Available only for authorised users

Scheie D, Meling TR, Cvancarova M, Skullerud K, Mork S, Lote K et al (2011) Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro-oncology 13(11):1225–1233CrossRef

Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. OncoTarget 5(6):1515–1525CrossRef

Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47(5):458–468CrossRef

Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR et al (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol 129(4):585–596CrossRef

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820CrossRef

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G et al (2020) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170–186CrossRef

Buckner JC, Chakravarti A, Curran WJ Jr (2016) Radiation plus chemotherapy in low-grade glioma. N Engl J Med 375(5):490–491PubMed

Karschnia P, Parsons MW, Dietrich J (2019) Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol 20(2):e92–e102CrossRef

Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK et al (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8(9):810–818CrossRef

10.

Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M et al (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360(9343):1361–1368CrossRef

11.

Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP et al (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981–990PubMed

12.

Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA et al (2017) Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro-oncology 19(2):242–251PubMed

13.

Ruda R, Pellerino A, Pace A, Carapella CM, Dealis C, Caroli M et al (2019) Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. J Neurooncol 145(1):115–123CrossRef

14.

Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD et al (2020) CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. Neuro-oncology 23(3):457–467CrossRef

15.

Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F et al (2016) Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-oncology 18(11):1529–1537PubMedPubMedCentral

16.

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 31(3):344–350CrossRef

17.

Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35):5874–5880CrossRef

18.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E et al (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18(6):e315–e329CrossRef

19.

Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ (2017) Response assessment in neuro-oncology clinical trials. J Clin Oncol 35(21):2439–2449CrossRef

20.

Suchorska B, Schuller U, Biczok A, Lenski M, Albert NL, Giese A et al (2019) Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. Eur J Cancer 107:15–27CrossRef

21.

Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113(3):379–385CrossRef

22.

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF et al (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology 13(6):649–659CrossRef

23.

Darvishi P, Batchala PP, Patrie JT, Poisson LM, Lopes MB, Jain R et al (2020) Prognostic value of preoperative MRI metrics for diffuse lower-grade glioma molecular subtypes. Am J Neuroradiol 41(5):815–821CrossRef

24.

Snyder LA, Wolf AB, Oppenlander ME, Bina R, Wilson JR, Ashby L et al (2014) The impact of extent of resection on malignant transformation of pure oligodendrogliomas. J Neurosurg 120(2):309–314CrossRef

25.

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337–343CrossRef

26.

Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE et al (2020) Comprehensive genomic analysis in NRG Oncology/RTOG 9802: A Phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 38(29):3407–3417CrossRef

27.

Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ et al (2012) Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 30(25):3065–3070CrossRef

Title: PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression
Authors: Jonathan Weller
Sophie Katzendobler
Philipp Karschnia
Stefanie Lietke
Rupert Egensperger
Niklas Thon
Michael Weller
Bogdana Suchorska
Joerg-Christian Tonn
Publication date: 01-06-2021
Publisher: Springer US
Keywords: Glioma
Glioma
Oligodendroglioma
Glioma
Cytostatic Therapy
Published in: Journal of Neuro-Oncology / Issue 2/2021
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-021-03765-z

2024 ASCO Annual Meeting

Springer Medicine

PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression

Abstract

Introduction

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2021

Primary and radiation induced skull base osteosarcoma: a systematic review of clinical features and treatment outcomes

Microsurgical resection of foramen magnum meningioma: multi-institutional retrospective case series and proposed surgical risk scoring system

Long-term outcomes of grade I/II skull base chondrosarcoma: an insight into the role of surgery and upfront radiotherapy

Clinical characteristics and management differences for grade II and III spinal meningiomas

Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival

Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma